Stock Details
4519.T is Chugai Pharmaceutical Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 3,592.32¥. Average daily volumn in 3 months 2.32M. Market cap 5.96T



Stock symbol : 4519.T. Exchange : Tokyo. Currency : JPY
Lastest price : 3,624.00¥. Total volume : 2.60M. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

Chugai Pharmaceutical Co., Ltd. (4519.T)
Last Price
3,624.00¥
Change
53.00
Volume
2.60M

Previous Close3,571.00
Open3,546.00
Day Range3,546.00-3,639.00
Bid3,623.00 x N/A
Ask3,626.00 x N/A
Volume2.6M
Average Volume2.32M
Market Cap5.96T
Beta0.64
52 Week Range3,258.00-4,490.00
Trailing P/E15.39
Foward P/E19.06
Dividend (Yield %)2.13%
Ex-Dividend Date2022-12-29



Financial Details


According to Chugai Pharmaceutical Co., Ltd.'s financial reports the company's revenue in 2021 were 999.76B an increase( +27.1%) over the years 2020 revenue that were of 786.95B. In 2021 the company's total earnings were 303B while total earnings in 2020 were 214.73B( +41.59%).


Loading ...



Organization

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept... , and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Market Cap:
5.96T
Revenue:
999.76B
Total Assets:
1.54T
Total Cash:
267.75B


News about "Chugai Pharmaceutical Co., Ltd."

Chugai Pharmaceutical Co., Ltd.

Source from : ニッケイ・エイジア - 7 days ago

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and ...See details»


Chugai Pharmaceutical Co Ltd - Stock Quote CUP

Source from : Morningstar%2c Inc. - 5 days ago

There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...See details»


Chugai Pharmaceutical Co Ltd - Stock Sustainability CHGCF

Source from : Morningstar%2c Inc. - 8 days ago

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.See details»


Japan to purchase antibody cocktail for Covid-19 treatment

Source from : Hindustan Times - 1 year ago

Chugai Pharmaceutical concluded the agreement with Roche in December for the production and marketing in Japan of the antibody cocktail for the virus treatment. A cocktail of two virus ...See details»


Spinal Muscular Atrophy Market To Surpass US$ 4,346.33 Million By 2030 - Coherent Market Insights'

Source from : Middle East North Africa Financial Network - 22 days ago

For instance, in June 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had obtained regulatory approval from the Ministry of Health, Labor and ...See details»


galderma-announces-positive-data-from-phase-iii-trial-demonstrating-efficacy-and-safety-of-nemolizumab-in-patients-with-prurigo-nodularis-image

Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis

Source from : Joplin Globe - 14 days ago

Galderma today announced the phase III OLYMPIA 2 trial met all primary and key secondary endpoints, showing nemolizumab as monotherapy significantly improved skin lesions and pruritus (itch) compared ...See details»


Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy

Source from : ascopubs.org - 2 month ago

Circulating tumor DNA (ctDNA) genotyping may guide targeted therapy for patients with advanced GI cancers. However, no studies have validated ctDNA genotyping for microsatellite instability (MSI) ...See details»


Angiogenesis Modulators Market Is Expected to Boom- ngstrom Pharmaceuticals, Inc., Merck & Co.

Source from : Digital Journal - 27 days ago

New Jersey, N.J., June 09, 2022 The Angiogenesis Modulators Market research report provides all the information related to the industry. It gives the outlook of the market by giving authentic data ...See details»


Chugai Pharmaceutical Co. Ltd. ADR

Source from : Wall Street Journal - 12 days ago

1 Day CHGCY 3.62% DJIA 2.68% S&P 500 3.06% Health Care/Life Sciences -1.01% Tatsuro Kosaka Chairman & Chief Executive Officer Chugai Pharmaceutical Co., Ltd., Asahi Group Holdings Ltd. Osamu Okuda ...See details»


Spinal Muscular Atrophy Market to Surpass US$ 4,346.33 Million by 2030 - Coherent Market Insights

Source from : Yahoo Finance - 22 days ago

For instance, in June 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had obtained regulatory approval from the Ministry of Health, Labor and ...See details»


CHGCY Chugai Pharmaceutical Co., Ltd.

Source from : Seeking Alpha - 21 days ago

**NM signifies a non meaningful value. A dash signifies the data is not available.See details»


Spinal Muscular Atrophy Market to Surpass US$ 4,346.33 Million by 2030 - Coherent Market Insights

Source from : WFMZ-TV - 22 days ago

For instance, in June 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had obtained regulatory approval from the Ministry of Health, Labor and ...See details»


Chugai Pharmaceutical Co. Ltd.

Source from : Barron's - 1 month ago

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...See details»


Spinal Muscular Atrophy Market to Surpass US$ 4,346.33 Million by 2030 - Coherent Market Insights

Source from : Finanznachrichten - 22 days ago

For instance, in June 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had obtained regulatory approval from the Ministry of Health, Labor and ...See details»